Search Results - Nai-Jung Chiang

  • Showing 1 - 1 results of 1
Refine Results
  1. 1
    Real-world efficacy of cabozantinib alone or in combination with ICIs in heavily pretreated hepatocellular carcinoma: potential role of AXL and MET expression

    Real-world efficacy of cabozantinib alone or in combination with ICIs in heavily pretreated hepatocellular carcinoma: potential role of AXL and MET expression by Kuan-Chang Lai, Te-Lin Hsu, Shih-Yao Lin, Nai-Jung Chiang, Ming‑Huang Chen, Yee Chao, Muh-Hwa Yang, San-Chi Chen

    Published 2025-07-01

    Introduction and Objectives: Cabozantinib, a multi-kinase inhibitor targeting AXL and MET, is approved for second-line treatment of hepatocellular carcinoma (HCC). However, the combination of cabozantinib with immune checkpoint inhibitors (ICIs) remains controversial after the COSMIC-312 study. The...

    Full description

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: